Abstract

Background Chronic hand eczema (CHE) is a well-recognized inflammatory disorder.
Objective To evaluate the efficacy and safety of 1.5% ruxolitinib cream in adults with moderate to severe CHE.
Methods This phase 2 study enrolled adults with CHE from North America and Europe, an Investigator's Global Assessment-CHE score of 3/4, ≥1 prior CHE therapy, and no current or recent history (≤5 y) of...